Kornimate/medical-research-clean huggingface dataset:
impact of 60 days powdered tart cherry supplementation on metabolic syndrome

Conditions: Metabolic Syndrome

Summary: metabolic syndrome (metsyn) is a growing health concern, with up to 25% of the worlds population having the syndrome. metsyn is a primary risk factor for cardiovascular disease and type ii diabetes development, and is independently associated with all-cause mortality, making it an important disease target. the primary treatment for metsyn is exercise and weight loss, along with medically necessary treatment. exercise, along with dietary changes such as increased fiber and polyphenol intake can positively impact many of the metabolic abnormalities seen with metsyn. for example, polyphenols have been shown to decrease lipid concentration and improved glucose clearance as well as decreased oxidative stress and inflammation. powdered tart cherry capsules, which contain the skin of the fruit, provides polysaccharides (fiber) that would likely act as a substrate for gut bacteria degradation, providing energy substrates and barrier integrity to the colonocytes and increasing the bioavailability of the polyphenols to other cells in the body. however there have been no long-term investigations into the use of powdered tart cherry supplements in metsyn, therefore we aim to determine if 60 days tart cherry supplementation modify criteria for metsyn in currently diagnosed individuals including body mass, waist circumference, blood pressure, blood lipid levels and blood glucose control.


Eligibility criteria:
inclusion criteria: * have been diagnosed with metabolic syndrome by a physician or meet the diagnostic criteria: waist circumference greater than 40 inches (men) or greater than 35 inches (women), high blood pressure (greater than 130/80) or taking medication for high blood pressure, high triglycerides (greater than 150 mg/dl) or low hdl (less than 40 for men, less than 50 for women), high fasting blood glucose (100-126 mg/dl) or diagnosed as pre-diabetic * age 25-60 exclusion criteria: * currently taking medication for glucose or lipid control, such as metformin and/or statin * currently using anti-inflammatory medications \& have not used corticosteroids in the last two months * diagnosed with or currently being treated for an inflammatory condition * major organ system impairment (heart failure, renal failure, severe impairment of respiratory function) * currently a smoker or quit less than 12 months ago
the efficacy of escitalopram for negative symptoms in schizophrenia

Conditions: Schizophrenia

Summary: the aim of this study is to evaluate the therapeutic effect of escitalopram in the treatment of negative symptoms in schizophrenia patients in a double-blind placebo-controlled study.

the aim of this study is to evaluate the therapeutic effect of escitalopram (cipralex) in the treatment of negative symptoms in schizophrenic patients receiving either typical or the newer atypical antipsychotics (olanzapine and risperidone) in a double-blind placebo-controlled study. as there is no drug treatment that is considered as first-line treatment in the treatment of negative symptoms, we thought that the comparison with placebo is plausible. however, it is important to note that the patients will receive the commonly used treatment for their disorder (i.e. antipsychotic medication).

Eligibility criteria:
inclusion criteria: * chronic schizophrenia patients, * age \<60, * medicated, * inpatients and outpatients,on stable doses of antipsychotic medications for at least one month before the study entry. * patients will be clinically stable and free of any additional axis i diagnosis or significant medical illnesses before enrollment into the study. * a positive and negative syndrome scale (panss) score of 50 or above will be required for entry to the study. exclusion criteria: * comorbidity with mania or major depression, * pregnancy, * lactation, * impaired renal or hepatic function, * history of sensitivity to cipramil or to other drugs from the selective serotonin reuptake inhibitor (ssri) group. * additional exclusion criteria will consist of mental retardation, organic conditions (brain tumors, drug abuse) and severe exacerbation of the psychiatric condition (i.e. suicide attempt, severe psychotic exacerbation) as defined by hospitalization in high-security units, clinical impression and cgi scores of "condition much worsened". * patients will be excluded during the study if they will remove their informed consent.

Keywords: negative symptoms depression ssri schizophrenia
the effect of shotblocker and cold massage on pain, crying time and physiological parameters in babies

Conditions: Vaccine; Pain

Summary: the aim of this study is to determine the effect of shotblocker© and cold massage on pain, crying time and physiological parameters during dabt-ipa-hib vaccine administration in 2-6 months old babies.

the aim of this study is to determine the effect of shotblocker© and cold massage on pain, crying time and physiological parameters during dabt-ipa-hib vaccine administration in 2-6 months old babies.this study was planned as randomized controlled experimental single-blind. the population of the research will be 2-6 months old babies who come to giresun güce district state hospital family health center to receive dabt-ipa-hib vaccine between the dates of the research. the sample of the study will consist of infants who met the case selection criteria, accepted to participate in the study and were vaccinated between the specified dates. as a result of the power analysis, it was determined that a total of 99 infants, 33 of whom were to be applied cold massage, 33 to be administered shotblocker©, and 33 to the control group, who were 2-6 months old to be administered dabt-ipa-hib vaccine, met the case selection criteria and agreed to participate in the study. considering the possibility of case losses, a total of 108 babies, 36 in each group, are planned to be included in the study.

Eligibility criteria:
inclusion criteria: * the baby is 2-6 months old, * dabt- ipa- hib vaccine will be administered, * the baby does not have a chronic disease, * parents must be at least primary school graduate, * parent's willingness to participate in the study. exclusion criteria: * having a congenital or neurological health problem, * have taken an analgesic drug in the last 4 hours, * babies with a body temperature above 37.5 will not be included in the study.
does coronary angiography cause cognitive dysfunction?

Conditions: Coronary Heart Disease; Heart Valve Diseases

Summary: the purpose of the study is to study if coronary angiography cause cognitive dysfunction.

we have previously shown, using transcranial doppler, that coronary angiography cause cerebral microembolism. cerebral microemboli were more common using the radial than femoral approach. previously, cerebral microembolism has been associated with new cerebral lesions on mri. the clinical significance of these new lesions is not determined. the primary aim of this pilot study is to see if coronary angiography cause cognitive dysfunction determined by the moca-test. a secondary aim is to relate cognitive dysfunction to cerebral microembolism measured by transcranial doppler. a third aim is to study potential differences between the femoral and radial approaches.

Eligibility criteria:
inclusion criteria: * elective coronary angiography irrespective of cause exclusion criteria: * previous cabg, language problems, not willing to participate
a study of tirzepatide (ly3298176) in pediatric participants with obesity

Conditions: Obesity

Summary: the main purpose of this study is to evaluate the safety and tolerability of tirzepatide (ly3298176) in pediatric participants with obesity. the blood tests will be performed to investigate how the body processes the study drug in these participants. for each participant, the study will last about approximately 13 weeks excluding the screening period.


Eligibility criteria:
inclusion criteria: * male and female participants with body mass index (bmi) ≥ the 95th percentile for age and sex * have failed to achieve adequate weight loss through lifestyle modification in the investigator's opinion * female participants only: determined as prepubertal tanner stage 1. exclusion criteria: * change in body weight above 5 kg (11 lbs) within 90 days before screening irrespective of medical records * have obesity induced by other endocrinologic disorders (for example, cushing syndrome) or diagnosed monogenetic or syndromic forms of obesity * have acute or chronic pancreatitis or a history of acute idiopathic pancreatitis; or have other gi disorders * have a known clinically significant gastric emptying, have undergone weight loss surgery such as gastric bypass (bariatric) surgery or restrictive bariatric surger, or have endoscopic or device-based therapy for obesity or have had device removal within the last 6 months. * have confirmed type 1 or type 2 diabetes mellitus * have a history or current cerebrovascular, respiratory, hepatic, renal, gi, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the ip; or may interfere with the interpretation of data

Keywords: pediatrics obesity chronic weight management
cerebral function monitoring in premature infants

Conditions: Infant, Newborn; Infant, Low Birth Weight; Infant, Small for Gestational Age; Infant, Premature; Electroencephalography

Summary: this observational study tests the feasibility of enrolling subjects and obtaining an amplitude-integrated electroencephalogram (aeeg) within the first 72 hours of life, a second aeeg recording between 72-168 hours of life, and weekly thereafter up to 36 weeks post-menstrual age. it will enroll 85-100 infants between 401-1,000 grams birth weight or between 23 0/7 and 28 6/7 weeks gestational age born at the 7 participating nichd neonatal research network sites.

few techniques exist to permit early and accurate prognosis of brain injury in newborns. cranial ultrasound and magnetic resonance imaging (mri) have been used to detect structural abnormalities which may be useful in predicting neuromotor and neurocognitive deficits. however, up to 30% of extremely low birth weight infants with normal ultrasounds have adverse outcomes, and mri is not feasible when an infant is critically ill. amplitude-integrated electroencephalogram (aeeg) is a non-invasive, bedside instrument which allows real-time monitoring of brain function and may provide additional information for predicting outcomes in extremely premature infants. this observational study will enroll 85-100 infants between 401-1,000 grams birth weight or between 23 0/7 and 28 6/7 weeks gestational age born at the 7 participating nichd neonatal research network sites. eligible infants will undergo an aeeg recording in the first 72 hours of life, a second aeeg recording between 72-168 hours of life, and weekly thereafter up to 36 weeks post-menstrual age. the study tests the feasibility of enrolling subjects and obtaining the required aeeg recordings. the information gathered will provide a framework for the design of a potential prospective, observational, multi-center study for prediction of death or neurodevelopmental impairment by 18-22 months of age.

Eligibility criteria:
inclusion criteria: * inborn infants * between 401 grams and 1,000 grams inclusive birth weight or between 23 0/7 and 28 6/7 weeks inclusive gestational age * decision to provide full intensive care support * less than 72 hours of age exclusion criteria: * non-intact skin at the central or parietal regions of scalp * presence of known or suspected congenital anomalies, including: * congenital central nervous system malformations * chromosomal anomalies or multiple congenital anomalies * complex congenital heart disease * inborn error of metabolism * acidosis (ph \ 2 hours) * persistent bradycardia \[hr \ 2 hours

Keywords: nichd neonatal research network very low birth weight (vlbw) extremely low birth weight (elbw) prematurity amplitude-integrated electroencephalography (aeeg)
transplantation of huc-mscs with injectable collagen scaffold for pof

Conditions: Premature Ovarian Failure

Summary: cellular therapies are rapidly progressing fields and have shown immense promise in the treatment of damaged ovarian function. the purpose of this study is to determine safety and efficacy of intra-ovarian injection of allogeneic huc-mscs with injectable collagen scaffold in women with premature ovarian failure (pof) and to study the preliminary efficacy of huc-mscs with injectable collagen scaffold injection on ovarian function improvement.

the purpose of this study was to explore the therapeutic potency of the huc-mscs with injectable collagen scaffold transvaginal injection for pof women. the serum of each patient was kept and sent for laboratory test before the surgery. huc-mscs were isolated and cultured in vitro and the biomarkers of huc-mscs were detected using flow cytometry detection. the huc-mscs with injectable collagen scaffold were then injected directly into bilateral ovaries. the outcomes of patients were examined after the injection. the patients are monitored for signs of follicle growth and growing follicles are stimulated with exogenous hormones, followed by oocyte retrieval and in vitro fertilization (ivf).

Eligibility criteria:
inclusion criteria: 1. diagnosed with premature ovarian failure. 2. patients show no response to drug treatment 3. women between 20 and 39 years. 4. willing to sign the informed consent form. exclusion criteria: 1. abnormal karyotyping (e.g. turner syndrome, fragile x syndrome). 2. congenital ovarian malformation. 3. severe endometriosis. 4. thyroid dysfunction. 5. contraindications for pregnancy. 6. contraindications for hormone replacement therapy. 7. prior personal history of ovarian cancer or after radiotherapy. 8. unwilling to comply with follow-up schedule or want to take other treatment during the follow-up period.
ganglionated plexi ablation combined with pulmonary vein isolation

Conditions: Persistent Atrial Fibrillation

Summary: the investigators have conducted a prospective, double-blind, randomized study to assess the comparative safety and efficacy of two different ablation strategies, pvi plus linear lesions (ll) versus pvi plus gp ablation, in patients with persistent or longstanding persistent af. results were assessed after follow-up of at least 3 years with the use of an implanted monitoring device (imd).


Eligibility criteria:
inclusion criteria: * persistent and longstanding persistent af exclusion criteria: * congestive heart failure * lv ejection fraction \< 35% * left atrial diameter \> 60 mm

Keywords: arrhythmias ablation
phase i study of dasatinib (bms-354825) and imatinib in subjects with chronic myeloid leukemia in chronic phase

Conditions: Myeloid Leukemia, Chronic, Chronic-Phase

Summary: the purpose of this study is to find out whether adding a new drug, dasatinib, to imatinib is safe, and whether the combination of the two drugs will help decrease the number of cells that contain the philadelphia chromosome.


Eligibility criteria:
inclusion criteria: * males and females, 18 or older * chronic phase ph+ or bcr-abl positive cml * current complete hematologic response to imatinib * lack of major molecular response * on imatinib for at least one year * on the same imatinib dose for at least 6 months * adequate hepatic and renal function exclusion criteria: * history of accelerated or blast phase cml * serious uncontrolled medical disorder or active infection * significant cardiovascular disease or bleeding disorder * concurrent use of medications at risk of causing torsades de pointe

Keywords: chronic phase chronic myelogenous leukemia (cml)
5-aminolevulinic acid (5-ala) gliolan®: usage increase proposal for neurosurgical procedures in high-grade gliomas

Conditions: High Grade Glioma; Glioma; Glioma, Malignant; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Photosensitizing Agents; Neoplasm Malignant; Brain Neoplasms, Adult, Malignant; Central Nervous System Neoplasms; Brain Tumor; Tumour, Residual

Summary: the goal of this observational study is to evaluate disease-free survival (dfs) in patients with malignant gliomas undergoing neurosurgical procedures using 5-aminolevulinic acid (5-ala)-based photodynamic therapy

the investigators are proposing a study that provides descriptive understanding of patients with high-grade gliomas in ecuador. the primary objective of this pilot study is to lay the foundations for the development of a multicenter registry patients with malignant gliomas undergoing neurosurgical procedures using 5-aminolevulinic acid (5-ala)-based photodynamic therapy, which will provide high-quality real data and serve as a basis for the application to future projects and elaboration of public policies in the medium and long term.

Eligibility criteria:
inclusion criteria: * age: 18 to 75 years (in pediatric cases will be included in the central nervous system (cns) tumor board to make decisions on therapeutic management) * patients with radiological suspicion (contrast uptake) of high-grade glioma (grade iii-iv) * patients with high-grade and residual glioma following surgery for gross total resection * patients with recurrent gliomas with reoperation criteria who previously received radiotherapy and chemotherapy * patients for whom at least one postoperative magnetic resonance imaging (mri) was available (up to 28 days after surgery and strictly before the start of radiotherapy) * progressing, low-grade infiltrative gliomas with one of the following criteria: * anaplastic foci with contrast uptake in mri * spectroscopy study in anaplastic suspected area with high malignancy criteria * positive choline pet-ct (positron emission tomography / computer tomography) exclusion criteria: * tumors extending across midline * basal ganglia tumor * brainstem tumor * multifocal gliomas * suspected low-grade glioma without anaplastic foci * neuraxial dissemination (ependymoma) * karnofsky grade less than 60% * infants or pregnant women * acute or chronic types of porphyria * non-acceptance of fluorescence-guided surgery * renal insufficiency confirmed by nephrological assessment * hepatic impairment confirmed by gastroenterological assessment * severe heart disease confirmed by cardiological assessment * decompensated diabetes confirmed by endocrinological assessment * known allergy to any contrast agent and/or previous history of anaphylactic shock * hypersensitivity to the active substance or porphyrins * asthma confirmed by pulmonological assessment * pacemaker use

Keywords: high grade glioma 5-ala aminolevulinic acid malignant glioma photodynamic therapy fluorescence-guided surgery photosensitizing agents tumor resection
multi-classifier system for stratifying stage iii papillary renal cell carcinoma of receiving adjuvant therapy

Conditions: Papillary Renal Cell Carcinoma

Summary: the goal of this trial is to test whether patients with stage iii papillary renal cell carcinoma (prcc) could benefit from adjuvant therapy or not. the investigators invented a multi-classifier system that was successfully categorise patients with stage iii prcc into high-risk and low-risk groups. here the investigators randomly assign classifier-defined high risk patients of stage iii prcc into adjuvant pembrolizumab group placebo group. disease-free survival and overall survival are the end points of observation.

kidney cancer represented 4.2% of all new cancer cases, and its incidence has been increasing. over 90% of kidney cancer cases are renal cell carcinoma (rcc), which includes various subtypes with distinct histologic features, clinical courses, and responses to therapy. clear cell renal cell carcinoma (ccrcc) and papillary renal cell carcinoma (prcc) are the most common histologic subtypes of rcc, accounting for approximately 75% and 20% of all cases, respectively. adjuvant pembrolizumab showed promising efficacy in ccrcc, however, whether high-risk prcc patients could benefit from adjuvant pembrolizumab remain unknown. participants will be assigned to continue with the study treatment until any of the following occurs: the recurrence of the disease; the emergence of unacceptable adverse events (aes); the presence of an intercurrent illness that precludes further administration of the treatment; the decision of the investigator to withdraw the participant; noncompliance with the study treatment or procedural mandates; administrative reasons necessitating the discontinuation of treatment; or the completion of 17 treatment cycles (approximately one year), with each cycle 3 weeks long.

Eligibility criteria:
inclusion criteria: * histological confirmation of prcc * with confirmed diagnosis of stage iii prcc * classified as high-risk by multi-classifier system * with moderate/good eastern cooperative oncology group (ecog) health rating (ps): 0-1 score. * receive radical operation for renal cancer with negative margin. * receive no anti-cancer treatment before primary surgery. * the informed consent has been obtained from the patient. exclusion criteria: * patients with transcription factor enhancer 3(tfe3) or transcription factor eb (tfeb) translocation proven by cytogenetic analysis or by fluorescence in situ hybridization (fish) * previously received neoadjuvant therapy * with severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction. * with bad compliance or contraindication to enrollment. * pregnant woman or lactating woman. * with contraindication to receive pembrolizumab, such as had a prior solid organ transplant, has a known history of human immunodeficiency virus infection.

Keywords: papillary renal cell carcinoma pembrolizumab adjuvant therapy
networks of bacterium-metabolite interactions in the small intestine

Conditions: Diet, Healthy; Microbial Colonization

Summary: probands with an ileo- or colostomy are assigned to consume a test meal which is either high in fat or high in carbohydrates. after the test meal samples from the stoma, urine, blood and skin are retrieved. these will be subjected to large scale analyses of microbiota and metabolite content. to get a better comparability test subjects will consume a standardized liquid diet three days before the study day.

between both study days a two week wash out phase will be done. during the study day sampling will be done at set time points until 8 hours after the consumption of the test meal.

Eligibility criteria:
inclusion criteria: * written informed consent * general good health * ileostomy or colostomy exclusion criteria: * hematologic disorders with contraindication of blood draw * participation in other clinical trial interfering with study protocol